A comprehensive view of Teva Pharmaceutical Industries Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves ANDA 208432 for Teva Pharmaceuticals’ oral abiraterone acetate 250 mg in one formulation; drug is available by prescription only, with 12 other prescription drugs with same dosage form, strength and active ingredient

Closing of Teva plant in Irvine, California, could result in shortages of 24 generic sterile injectable drugs, including five drugs that accounted for 15% of the market last year; operations at plant stopped after FDA concerns about contamination

Teva recalls one lot of cancer drug anagrelide in 0.5-mg capsules in the US because capsule doesn’t dissolve properly, which could hamper, nullify drug’s effectiveness; recall involves 4,224 100-count bottles released between July 30 and Sept. 2, 2020

Teva swings to Q1 net loss of US$955.0M from net profit of US$77.0M a year ago, with revenue down 8% year-over-year to US$3.7B; decline attributed to costs of opioid-related litigations, generic drug competition affecting Copaxone glatiramer acetate sales

FDA rejects bid by Teva, MedinCell for approval of new extended-release version of subcutaneous risperidone to treat schizophrenia after positive Phase 3 results; Teva to pursue resolution of matter but analyst expects approval delay of nine to 12 months

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count